What is Synakis?
Synakis is a pre-clinical biotechnology firm dedicated to advancing treatments for serious ocular conditions, including retinal detachment and glaucoma. The company's proprietary technology, SNK-125, is an injectable hydrogel engineered for precise ocular delivery. This innovative biomaterial aims to restore vision and enhance patient quality of life by offering biocompatible and biodegradable solutions to address leading causes of blindness. Synakis actively engages with the scientific and medical communities to disseminate its research findings and technological advancements in ophthalmic therapies.
How much funding has Synakis raised?
Synakis has raised a total of $1.9M across 1 funding round:
Angel/Pre-Seed
$1.9M
Angel/Pre-Seed (2026): $1.9M with participation from Ontario Centre of Innovation, Canadian Glycomics Network, and Toronto Innovation Acceleration Partners
Key Investors in Synakis
Ontario Centre of Innovation
The Ontario Centre of Innovation (OCI) is a provincial agency focused on commercializing research and fostering innovation across key sectors in Ontario, supporting the development of next-generation entrepreneurs and technologies in areas like advanced health and materials.
Canadian Glycomics Network
The Canadian Glycomics Network (GlycoNet) is a leading research network dedicated to developing carbohydrate-based solutions for global health and agri-food challenges, with a focus on drug discovery and diagnostics.
Toronto Innovation Acceleration Partners
Toronto Innovation Acceleration Partners (TIAP) specializes in building early-stage health science ventures from academic research, providing financial and scientific expertise to de-risk innovations and connect them with investors and industry.
What's next for Synakis?
The recent major strategic investment signals a pivotal growth phase for Synakis, likely enabling the company to advance its SNK-125 technology through further pre-clinical development and potentially into clinical trials. This capital infusion is expected to bolster research and development efforts, expand the scientific team, and support the rigorous regulatory pathways required for novel therapeutic agents. The company's focus on biomaterial-based solutions for blindness positions it to capture a significant share of the expanding ophthalmic treatment market.
See full Synakis company page
